Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 2,216 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Blinded (placebo) Clear all

Conditions: Osteoarthritis of Hip, Regional Anesthesia, Other Acute Postoperative Pain, Total Hip Arthroplasty, Peripheral Nerve Block, Lumbar Plexus Nerve Block, Parasacaral (Sciatic) Nerve Block
Interventions: Continuous Lumbar Plexus Block, Parasacral Nerve Block, Ropivacine 0.2%, Bupivacaine 0.0625%; Procedure · Drug
Lead sponsor: Rita Merman; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteoporosis, Breast Cancer
Interventions: Not listed
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years and older · Female only
Enrollment: 351 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2022
U.S. locations: 2
States / cities: Sacramento, California • Rochester, Minnesota

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Minimal (Trophic) Feeding, Full Feeding, Omega-3 Fatty Acids and Antioxidant Supplements, Placebo; Behavioral · Dietary Supplement
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 13 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 41
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 20 more

Conditions: Diabetic Neuropathy
Interventions: JNJ-42160443 (1 mg), JNJ-42160443 (3 mg), JNJ-42160443 (10 mg), Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 23
States / cities: Jonesboro, Arkansas • Fresno, California • La Jolla, California + 20 more

Conditions: Infantile Colic
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: The Archer-Daniels-Midland Company; Industry
Eligibility: 3 Weeks to 12 Weeks
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alcohol Use Disorder
Interventions: Acamprosate, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Center City, Minnesota • Rochester, Minnesota • Newberg, Oregon

Conditions: Colitis
Interventions: Vancomycin, Saline; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Colorectal Cancer, Coffee, Gastrointestinal Microbiome, Stenosis, Fibrosis, Liver, Ultrasound Elastography, Proton Magnetic Resonance Spectroscopy
Interventions: Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule., Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions: benralizumab, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Cancer
Interventions: Aspirin, Placebo for Aspirin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-melanomatous Skin Cancer, Precancerous/Nonmalignant Condition
Interventions: eflornithine, triamcinolone; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
Interventions: ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV), Placebo for ABT-267; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more

Conditions: Eosinophilic Esophagitis
Interventions: QAX576 placebo, QAX576; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Stanford, California • Chicago, Illinois • Minneota, Minnesota + 2 more

Conditions: Cerebral Palsy
Interventions: Cord Blood Infusion, Intravenous Sham; Biological
Lead sponsor: Augusta University; Other
Eligibility: 1 Year to 12 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Analgesic Adverse Reaction
Interventions: Ketorolac Tromethamine, 0.9% Normal Saline; Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 2 Years to 18 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Albany, New York

Conditions: Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
Interventions: Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo, FreeStyle Libre Pro, Deuterated water (2H2O/D2O); Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Plantar Fasciitis
Interventions: transdermal CBD cream (Tolcylen®, Marlinz Pharma), Matched Placebos; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Metabolic Acidosis
Interventions: TRC101, Placebo; Drug
Lead sponsor: Tricida, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Hialeah, Florida + 4 more

Conditions: Chronic Tympanic Membrane Perforation
Interventions: Fibroblast Growth Factor 2, Saline control; Drug
Lead sponsor: D. Bradley Welling, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma
Interventions: Atezolizumab, Atezolizumab Placebo, Cobimetinib, Vemurafenib, Vemurafenib Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Tempe, Arizona • Springdale, Arkansas + 4 more

Conditions: Arthritis, Psoriatic
Interventions: Apremilast (CC-10004), Apremilast (CC-10004) Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 54
States / cities: Mesa, Arizona • Covina, California • Encino, California + 48 more

Conditions: Myocardial Ischemia
Interventions: Metoprolol, Esmolol, P-Group; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Premature Birth
Interventions: Betamethasone - ACTIVE, Normal Saline - PLACEBO; Drug · Other
Lead sponsor: Pediatrix; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 6 more

Conditions: Meningococcal Vaccine
Interventions: MenABCWY, Saline, Trumenba, MenACWY-CRM; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 2,431 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 61
States / cities: Birmingham, Alabama • Tempe, Arizona • Banning, California + 49 more

Search by objective public record fields.

Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement

Effects of Exemestane on Bone Strength

Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome

Intracolonic Vancomycin Therapy in Severe C. Diff Colitis

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

ASPirin Intervention for the REDuction of Colorectal Cancer Risk

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis

Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children

Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy

Glycemic Effect of Diazoxide in NAFLD

A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis

Long-term Safety Extension to Study TRCA-301

In-office Repair of Chronic Tympanic Membrane Perforations

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement

Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age